Epstein Secrets

g it a `giant logistical project;" and he "said the GSA's stonewalling is making that difficult." The AP (11/15, Alonso-Zaldivar, Weissert) reports Klain "said Biden's experts also need a detailed understanding of distribution plans being finalized by the Department of Health and Human Services and t

dlined "Biden Turns Up Pressure for Administration Recognition" provides similar coverage, as does the Washington Times (11/15, 492K), which reports Klain "said Mr. Biden's team will begin consulting with Pfizer and other vaccine makers this week but they would like to be able to speak with key offici

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

g it a `giant logistical project;" and he "said the GSA's stonewalling is making that difficult." The AP (11/15, Alonso-Zaldivar, Weissert) reports Klain "said Biden's experts also need a detailed understanding of distribution plans being finalized by the Department of Health and Human Services and t

dlined "Biden Turns Up Pressure for Administration Recognition" provides similar coverage, as does the Washington Times (11/15, 492K), which reports Klain "said Mr. Biden's team will begin consulting with Pfizer and other vaccine makers this week but they would like to be able to speak with key offici

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

g it a `giant logistical project;" and he "said the GSA's stonewalling is making that difficult." The AP (11/15, Alonso-Zaldivar, Weissert) reports Klain "said Biden's experts also need a detailed understanding of distribution plans being finalized by the Department of Health and Human Services and t

dlined "Biden Turns Up Pressure for Administration Recognition" provides similar coverage, as does the Washington Times (11/15, 492K), which reports Klain "said Mr. Biden's team will begin consulting with Pfizer and other vaccine makers this week but they would like to be able to speak with key offici

g maker to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying